Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Multiple myeloma gammopathies

Comparative analysis of staging systems in AL amyloidosis

Subjects

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2

References

  1. D'Souza A, Dispenzieri A, Wirk B, Zhang MJ, Huang J, Gertz MA, et al. Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: A Center for International Blood and Marrow Transplant Research Study. J Clin Oncol. 2015;33:3741–9.

    Article  CAS  Google Scholar 

  2. Muchtar E, Gertz MA, Kumar SK, Lacy MQ, Dingli D, Buadi FK, et al. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood. 2017;129:2111–9.

    Article  CAS  Google Scholar 

  3. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22:3751–7.

    Article  CAS  Google Scholar 

  4. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30:989–95.

    Article  CAS  Google Scholar 

  5. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, et al. Long-term survival (10 years or more) in 30 patients with primary amyloidosis. Blood. 1999;93:1062–6.

    Article  CAS  Google Scholar 

  6. Dispenzieri A, Lacy MQ, Kyle RA, Therneau TM, Larson DR, Rajkumar SV, et al. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol. 2001;19:3350–6.

    Article  CAS  Google Scholar 

  7. Palladini G, Kyle RA, Larson DR, Therneau TM, Merlini G, Gertz MA. Multicentre versus single centre approach to rare diseases: the model of systemic light chain amyloidosis. Amyloid. 2005;12:120–6.

    Article  Google Scholar 

  8. Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013;121:3420–7.

    Article  CAS  Google Scholar 

  9. Kumar S, Dispenzieri A, Katzmann JA, Larson DR, Colby CL, Lacy MQ, et al. Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood. 2010;116:5126–9.

    Article  CAS  Google Scholar 

  10. Kourelis TV, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, et al. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. J Clin Oncol. 2013;31:4319–24.

    Article  CAS  Google Scholar 

  11. Bochtler T, Hegenbart U, Kunz C, Granzow M, Benner A, Seckinger A, et al. Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens. J Clin Oncol. 2015;33:1371–8.

    Article  CAS  Google Scholar 

  12. Muchtar E, Dispenzieri A, Kumar SK, Ketterling RP, Dingli D, Lacy MQ et al. Interphase fluorescence in-situ hybridization (iFISH) in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category. Leukemia 2017;31:1562–1569.

  13. Muchtar E, Dispenzieri A, Kumar SK, Buadi FK, Lacy MQ, Zeldenrust S et al. Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. Leukemia 2017; 31:92–99.

    Article  Google Scholar 

  14. Palladini G, Sachchithanantham S, Milani P, Gillmore J, Foli A, Lachmann H, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015;126:612–5.

    Article  CAS  Google Scholar 

  15. Pencina MJ, D’Agostino RB Sr., D’Agostino RB Jr., Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157–72. discussion 207–112

    Article  Google Scholar 

Download references

Acknowledgements

The study was supported by the Jabbs Foundation (Birmingham, United Kingdom), the Henry J. Predolin Foundation (USA), and National Institutes of Health National Cancer Institute grant P50 CA186781.

Authors contributions

EM designed the study, analyzed the data, wrote the first draft and approved the final version of the manuscript. TMT and DRL designed the study, did the statistical analysis, revised the manuscript critically and approved the final version of the manuscript. MAG, MQL, FKB, DD, SRH, PK, WG, TVK, RW, AF, MH, YLH, NL, SR, JAL, YL, RSG, SZ, SVR, SKK performed patient management, revised the manuscript critically, and approved the final version of the manuscript. RAK performed patients’ follow-up, revised the manuscript critically, and participated in final data analysis and approval of the final version of the manuscript; AD designed the study, analyzed the data, wrote the first draft, and approved the final version of the manuscript, performed patient management.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Angela Dispenzieri.

Ethics declarations

Conflict of interest

MAG: Consultancy (Milleniu) and honoraria (Celgene, Millenium, Onyx, Novartis, Smith Kline, Prothena, Ionis); MQL: Research funding (Celgene); DD: Research funding (Karyopharm Therapeutics, Amgen, and Millenium Pharmaceuticals); PK: Research funding (Takeda, Celgene, and Amgen); SKK: Consultancy (Celgene, Millennium, Onyx, Janssen, and BMS) and research funding (Celgene, Millennium, Novartis, Onyx AbbVie, Janssen, and BMS); AD: Research funding (Celgene, Millennium, Pfizer, and Janssen), Travel grant (Pfizer). The remaining authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Muchtar, E., Therneau, T.M., Larson, D.R. et al. Comparative analysis of staging systems in AL amyloidosis. Leukemia 33, 811–814 (2019). https://doi.org/10.1038/s41375-018-0370-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-018-0370-z

This article is cited by

Search

Quick links